Recently, appointed Vice-President of Computational Sciences at Novasenta, a UPMC Enterprise Company. Leading an experienced computational team to discover and develop novel cancer immune-therapeutics. Ph.D. scientist with 25 plus years experience leading computational biology support for drug, vaccine and consumer health projects from early target discovery through launched products. While at GlaxoSmithKline, led multidisciplinary teams focused on target discovery and validation in a complex, matrixed business environment including pharma, biotech and public-private partnerships. Specific areas of expertise include host-pathogen interactions, microbiome, human genetics and genomics and infectious, respiratory and immune-related diseases. Developed an innovative strategy for integration of human genetics and functional genomics to identify novel host-pathogen targets. As Executive Director and Head of Computational Biology and Integrated Data Science for Kaleido Biosciences, contributed to the discovery and clinical development of microbiome modulators for infectious and inflammatory diseases. Initiator and co-lead for a novel COPD therapy targeting the gut-lung microbiome axis. Significant external scientific profile with 118 publications including Nature journals, PNAS and EMBO as well as numerous speaker and advisory panel invitations. Experienced group leader and mentor of early and mid-career scientists with a strong record of positive and inclusive recruitment and dedication to talent development.